11/24/2014 3:30 PM IPN.PA 42.10 € (+1.42 %) Data: Yahoo Finance
Startsidan

Press Releases

  • 11/20/2014

    Ipsen and CNRS create the “Archi-Pex” joint research and innovation lab, in collaboration with the University of Rennes 1 and CEA

    Ipsen and CNRS create the “Archi-Pex” joint research and innovation lab, in collaboration with the University of Rennes 1 and CEA
  • 11/18/2014

    Ipsen and the Salk Institute renew their agreement for discovery research in medical sciences

    Ipsen and the Salk Institute renew their agreement for discovery research in medical sciences
  • 11/6/2014

    Otonomy obtains rights to gacyclidine data from Ipsen to support development of OTO-311 as a treatment for tinnitus

    Otonomy obtains rights to gacyclidine data from Ipsen to support development of OTO-311 as a treatment for tinnitus
  • 10/29/2014

    Ipsen: sales in the 3rd quarter and first nine months of 2014

    Ipsen: sales in the 3rd quarter and first nine months of 2014
  • 10/22/2014

    Lexicon and Ipsen enter into ex-North America/Japan licensing and commercialization agreement for telotristat etiprate

    Lexicon and Ipsen enter into ex-North America/Japan licensing and commercialization agreement for telotristat etiprate
  • 10/10/2014

    Ipsen announces positive results from phase III clinical study of Decapeptyl® (triptorelin pamoate) 11.25 mg administered by subcutaneous route to prostate cancer patients

    Ipsen announces positive results from phase III clinical study of Decapeptyl® (triptorelin pamoate) 11.25 mg administered by subcutaneous route to prostate cancer patients
  • 10/10/2014

    Aymeric Le Chatelier joins Ipsen as Executive Vice President, Chief Financial Officer

    Aymeric Le Chatelier joins Ipsen as Executive Vice President, Chief Financial Officer
  • 10/2/2014

    Susheel Surpal steps down as Executive Vice President, Chief Financial Officer of Ipsen to pursue other opportunities

    Susheel Surpal steps down as Executive Vice President, Chief Financial Officer of Ipsen to pursue other opportunities
  • 9/27/2014

    Ipsen presents preliminary results of exploratory proof-of-concept study with tasquinimod in four advanced tumor types at the ESMO 2014 Congress

    Ipsen presents preliminary results of exploratory proof-of-concept study with tasquinimod in four advanced tumor types at the ESMO 2014 Congress
  • 9/1/2014

    Ipsen announces acceptance of filings for Somatuline® in the treatment of GEP-NETs in the US with priority review and in Europe

    Ipsen announces acceptance of filings for Somatuline® in the treatment of GEP-NETs in the US with priority review and in Europe